Mkts

Larimar Therapeutics, Inc.

NASDAQ: LRMR
$2.35+0.08 (+3.52%)
As of Oct 23, 9:30 AM ET

Key statistics

Day range
2.222.37
52-week range
1.926.42
Today
Open2.27
Previous close2.35
Volume1.14M
Valuation
Market cap252.44M
P/E ratio—
EPS (TTM)-1.99
Income & risk
Dividend / yield—
Beta0.69
Avg volume2.11M
Discussion

LRMR News

Stories mentioning LRMR from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue
Cost of Goods Sold
Gross Profit0.000.000.000.000.000.000.000.00
Operating Expenses
Research & Development25,03159,37344,93123,36826,55226,73813,91919,682
Sales General & Admin
Total Operating Expenses31,11764,01849,49927,79231,18831,29318,26424,599
Operating Income (Loss)(31,117)(64,018)(49,499)(27,792)(31,188)(31,293)(18,264)(24,599)
Interest Income
Interest Expense
Other Expense
Pretax Income
Tax Provision0.000.000.000.00
Net Income (Loss)(29,613)(62,498)(47,712)(26,182)(29,281)(28,824)(15,499)(21,627)
Earnings Per Share (Basic)(0.61)(0.41)(0.46)(0.47)(0.24)(0.34)
Earnings Per Share (Diluted)(0.61)(0.41)(0.46)(0.47)(0.24)(0.34)
Weighted Average Shares Outstanding (Basic)78,32564,02863,96461,25663,80663,802
Weighted Average Shares Outstanding (Diluted)78,32564,02863,96461,25663,80663,802

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About LRMR

Larimar Therapeutics, Inc. (NASDAQ: LRMR) is a stock listed on the Nasdaq Stock Market under the ticker symbol LRMR. It last traded at $2.35 (Oct 23, 2026, 9:30 AM ET), up 3.5% on the day. That gives Larimar Therapeutics a market capitalisation of $252.4M.

Over the past 52 weeks LRMR has traded between $1.92 and $6.42.

For the quarter ended Mar 31, 2026 it reported a net loss of $29.6M.

Last 4 quarters
Quarter endedRevenueNet income
Mar 31, 2026—-$29.6M
Dec 31, 2025—-$62.5M
Sep 30, 2025—-$47.7M
Jun 30, 2025—-$26.2M

From Larimar Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…